70 citations
,
September 2017 in “Expert opinion on therapeutic patents” The review suggests that while many AKR1C3 inhibitors show promise for treating certain cancers, more research is needed to confirm their effectiveness in humans.
July 2024 in “Journal of Investigative Dermatology” DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.
1 citations
,
January 2023 in “SAGE open medical case reports” A new treatment called deucravacitinib helped a patient with severe hair loss grow their hair back quickly.
March 2025 in “Clinical and Experimental Dermatology” Older patients without prior JAK inhibitor treatment respond best to tofacitinib for alopecia areata.
78 citations
,
March 2004 in “Annals of Oncology” The treatment combining docetaxel, cisplatin, and 5-FU is feasible and effective for advanced head and neck cancer.
Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.
January 2025 in “Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)” Baricitinib is effective and safe for treating severe alopecia areata.
September 2023 in “Journal of the American Academy of Dermatology” Oral difelikefalin significantly reduces itch in notalgia paresthetica.
1 citations
,
March 2024 in “Journal of Cellular and Molecular Medicine” 4-octyl itaconate may prevent hearing loss caused by the drug cisplatin by activating certain cell protection pathways.
June 2024 in “Poster presentations” Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.
Baricitinib works better than methotrexate for severe alopecia areata.
May 2025 in “Frontiers in Pharmacology” Targeting gut microbiome and metabolome may help treat autoimmune skin diseases like alopecia areata.
October 2006 in “Clinical Cancer Research” Antioxidants can block the cancer-fighting effects of doxorubicin.
April 2007 in “Nature Clinical Practice Urology” TICE salvage chemotherapy is effective for treating germ-cell tumors with poor prognosis.
24 citations
,
July 2021 in “Pharmaceutics” Ruxolitinib cream effectively targets and treats inflammatory skin diseases.
4 citations
,
April 2016 in “Journal of The American Academy of Dermatology” A patient with advanced kidney cancer and no hepatitis C developed skin inflammation due to a drug called interferon alpha-2a.
16 citations
,
February 2019 in “Pediatric Blood & Cancer” Most children with CNS tumors on targeted therapy had skin reactions, which were generally treatable without stopping the therapy.
January 2025 in “Recent Patents on Anti-Cancer Drug Discovery” The treatment showed high response rates and was well-tolerated, potentially extending patient survival.
8 citations
,
August 2018 in “BMJ Case Reports” Pazopanib treatment caused rapid hair color loss, possibly indicating its effectiveness.
August 2025 in “Journal of the American Academy of Dermatology” 701 citations
,
August 2014 in “Nature medicine” Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
16 citations
,
January 2017 in “Archives of Medical Science” Sorafenib after liver surgery may increase survival for some liver cancer patients.
12 citations
,
September 2015 in “Drug Design Development and Therapy” AD198 is more effective than doxorubicin in stopping certain dog cancer cells.
4 citations
,
November 2017 in “The Journal of Dermatology” Sorafenib may cause hair loss in a way similar to alopecia areata.
7 citations
,
January 2017 in “Dermatology Online Journal” TNF-inhibitor induced alopecia can be treated effectively with different therapies.
December 2025 in “Pediatric Dermatology” Trametinib can cause skin issues, but they can often be managed without stopping the drug.
1 citations
,
January 2020 in “Surgical & Cosmetic Dermatology” Combining oral minoxidil with JAK inhibitors helps regrow hair in severe alopecia areata cases.
68 citations
,
January 2013 in “BMC Pharmacology and Toxicology” Glibenclamide slows breast cancer cell growth by stopping cell division.
12 citations
,
March 2021 in “JAAD Case Reports” Nail changes from immunotherapy can be managed without stopping cancer treatment.
March 2018 in “Suez Canal University Medical Journal” New drugs targeting the JAK-STAT pathway show promise for treating inflammatory skin diseases.